Group 1 - The core point of the announcement is that Yunnan Baiyao Group has received notification from its shareholder, Xinhua Dou Industrial Group, regarding the pledge of a portion of its shares [1] - Xinhua Dou has pledged 6,750,000 shares, which represents 1.50% of the shares held by Xinhua Dou and its concerted parties, and 0.38% of Yunnan Baiyao's total share capital [2] - The cumulative pledged shares amount to 80,250,000, accounting for 17.85% of the shares held by Xinhua Dou and its concerted parties, and 4.50% of Yunnan Baiyao's total share capital [2] Group 2 - The pledged shares do not bear any significant asset restructuring or performance compensation obligations [1] - The company will fulfill its information disclosure obligations in a timely manner if there are any significant changes regarding the pledged shares [3] - Relevant documents related to the share pledge have been prepared for reference, including the securities pledge registration certificate and detailed lists of pledged and judicially frozen securities [4]

质押股份是否负担重大资产重组等业绩补偿义务：否。 1 / 3 股票代码：000538 股票简称：云南白药 公告编号：2026-02 云南白药集团股份有限公司 关于股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）于近 日接到公司股东新华都实业集团股份有限公司（以下简称"新华都"）的通 知，获悉新华都将其持有的公司部分股份办理了质押。具体情况如下： 股东名 称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质押数 量（股） 占其所 持股份 比例 占公司 总股本 比例 是否为限 售股（如 是，注明 限 售 类 型） 是否 为补 充质 押 质押起始日 质押 到期 日 质权人 质押 用途 新华都 实业集 团股份 有限公 司 否 6,750,000 1.55% 0.38% 否 否 2026-02-02 至办 理解 除质 押之 日止 兴业银 行股份 有限公 司福州 分行 融资 担保 合计 / 6,750,000 1.55% 0.38% / / / / / / 一、本次股份质押基本情况 ...

Market Overview - The Chinese traditional medicine sector increased by 0.73% on February 3, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Stock Performance - Foci Pharmaceutical (002644) closed at 9.65, rising by 4.78% with a trading volume of 335,000 shares and a transaction value of 314 million yuan [1] - Other notable performers include: - Bichang Pharmaceutical (603858) at 17.52, up by 3.98% [1] - Zhendong Pharmaceutical (300158) at 5.76, up by 3.04% [1] - Dong'e Ejiao (000423) at 52.90, up by 2.94% with a transaction value of 800 million yuan [1] Capital Flow - The traditional medicine sector experienced a net outflow of 193 million yuan from institutional investors, while retail investors saw a net inflow of 190 million yuan [2] - The capital flow for key stocks includes: - Bichang Pharmaceutical with a net inflow of 42.06 million yuan from institutional investors [3] - Foci Pharmaceutical with a net inflow of 14.63 million yuan from institutional investors [3] - Dong'e Ejiao had a net inflow of 12.57 million yuan from institutional investors [3]

Core Viewpoint - The article emphasizes the importance of health and wellness, particularly for individuals over 40, highlighting the need to take care of oneself to support family responsibilities and well-being [5][8][9]. Group 1: Health and Wellness - Individuals over 40 who have healthy parents and a stable family are considered to be at the top of the social pyramid [5]. - Taking care of one's health is not just a personal matter but a significant concern for the entire family [9]. - True wellness is described as a long-term commitment rather than a temporary trend or luxury [11]. Group 2: Yunnan Baiyao Brand - Yunnan Baiyao is presented as a century-old national brand, established in 1902, known for its quality and trustworthiness [15][16]. - The brand has a rich history, having been recognized and supported by historical figures, including Premier Zhou Enlai [18]. - Yunnan Baiyao's products are based on a secret formula that has been validated by generations of users, establishing a strong reputation [21]. Group 3: Product Offerings - The article promotes various health products, including broken wall ganoderma spore powder, western ginseng, and saffron, available at discounted prices during a live broadcast event [13][28]. - The broken wall ganoderma spore powder is highlighted for its high bioavailability and health benefits, including immune support and anti-aging properties [40][41]. - The article also mentions the three-seven powder, which is known for its blood circulation benefits, and emphasizes its quality through rigorous testing [54][56]. Group 4: Promotional Event - A promotional live broadcast event is scheduled for February 4, featuring significant discounts on health products, encouraging early reservations [27][28]. - The event aims to provide affordable health solutions, with prices as low as 9.9 yuan for certain products, making them accessible to a wider audience [28][29]. - The article encourages participation in the live event to secure exclusive offers and learn about the products from experts [27][76].

Industry Overview - The gynecological medication industry encompasses drugs for the prevention, diagnosis, and treatment of gynecological diseases, including traditional hormone therapies, antibiotics, analgesics, and immunomodulators [1][3] - The market for gynecological medications in China has shown rapid growth, with the market size increasing from 27.735 billion yuan in 2012 to an estimated 56.137 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 6.05% [1][9] - By 2025, the market size is projected to reach approximately 59.53 billion yuan, driven by increasing awareness of women's health and societal emphasis on female health [1][9] Market Dynamics - The prevalence of gynecological diseases among adult women in China is high, with an estimated incidence rate between 40% and 70%, including conditions such as tumors, cysts, reproductive-related diseases, and gynecological inflammation [6] - The rise in gynecological disease rates and the growing health consciousness among women are contributing to the steady expansion of the gynecological medication market [6] Industry Chain - The gynecological medication industry chain consists of upstream raw materials, intermediates, and pharmaceutical equipment; midstream production; and downstream distribution through pharmacies, hospitals, and e-commerce platforms [6][7] Key Companies - Notable companies in the gynecological medication sector include Qianjin Pharmaceutical, Tongrentang, Kangyuan Pharmaceutical, Jiuzhitang, Yunnan Baiyao, and others, which are focusing on R&D and product differentiation [10][11] Development Trends - Future product development in gynecological medications is expected to shift towards precision and individualized treatment, utilizing diagnostic technologies to enhance treatment efficacy and reduce side effects [12] - Innovations in drug formulations and delivery methods will improve patient compliance and experience, with a focus on long-acting, user-friendly options [13] - The role of gynecological medication companies is evolving from mere drug suppliers to providers of comprehensive health management solutions for women throughout their life stages [14]

Core Insights - The pharmaceutical industry is increasingly adopting AI technologies, with over 60% of pharmaceutical companies and more than half of public hospitals using DingTalk as an AI operating system to enhance productivity [1][2] - AI is transforming the pharmaceutical sector by enabling companies to shift from repetitive tasks to more strategic roles, thereby enhancing operational efficiency [1][2] - DingTalk's AI application white paper indicates that AI is moving from exploration to large-scale application across the pharmaceutical value chain, impacting drug discovery, production, quality control, and patient services [1][2] Industry Developments - The pharmaceutical industry is characterized by high specialization, strong regulation, and long supply chains, making AI implementation a systemic transformation rather than just a technological upgrade [2] - DingTalk's AI solutions have been successfully implemented in various pharmaceutical companies, including WuXi AppTec and Innovent Biologics, and the company plans to launch a "Digital Pioneer Competition" to cultivate AI-savvy individuals within 100 pharmaceutical firms [2][3] - The establishment of the "Pharmaceutical Industry AI Innovation Alliance" aims to address common challenges such as data governance and ethical standards, promoting best practices for AI development in the sector [2][3] Company Case Studies - WuXi AppTec and DingTalk have developed a digital foundation called "BaiYaoDing," integrating AI into various processes, including traditional Chinese medicine traceability and smart factory production [2][3] - Innovent Biologics focuses on fine management in production through AI, achieving digitalization and transparency in anomaly handling, which has led to significant labor savings and improved quality [3] - Lepu Medical's AI initiatives provide 24/7 professional knowledge support to sales teams, resulting in a 200% return on AI investment by 2025, demonstrating AI's direct value in driving business growth [3] - Xianle Health has utilized AI tools to create an intelligent inspection application, enhancing management efficiency and fostering a culture of innovation within the organization [3][4] Future Outlook - AI is becoming a core driver of quality improvement, efficiency, and innovation in the pharmaceutical industry, with ongoing advancements in technology and a thriving ecosystem [4]

Group 1 - Yunnan Province ranks first globally in the production of tin, indium, and germanium, and has the most complete platinum group metals and titanium industry chain in China [2][3] - The province is recognized as a major agricultural hub in China, with significant achievements in highland characteristic agriculture, including the highest global production of flowers and the largest number of organic product certifications in China [2][3] - Yunnan is a leader in ecological civilization, achieving the highest ranking in China for the assessment of civilized, healthy, and environmentally friendly lifestyles for two consecutive years, and aims for a 98.9% rate of good air quality days by 2025 [3] Group 2 - Yunnan Baiyao has been recognized as the world's first "Lighthouse Factory" in the field of traditional Chinese medicine health products, showcasing the highest level of intelligent manufacturing and digitalization [4] - The province has established a new advantage in "green electricity + advanced manufacturing," with major hydropower projects like the Wudongde and Baihetan power stations contributing to a total installed capacity exceeding 170 million kilowatts, ranking high in green electricity capacity and proportion in China [4]

Group 1 - Yunnan Baiyao announced that it will accept a research visit from Guotai Junan on January 23, 2026, with representatives from the company participating in the meeting [1] - The company’s securities affairs representative and investor relations management will address questions raised by investors during the visit [1] Group 2 - International gold prices have surpassed $5,000, marking a 280% increase over the past seven years [1] - Experts suggest that the future trajectory of gold prices will depend significantly on the U.S. dollar, as well as factors such as the international monetary system, interest rate cuts, and technological revolutions [1]

Group 1: Marketing Strategies - The Pharmaceutical Business Group focuses on becoming the "first brand" in pain management, leveraging the efficacy of Yunnan Baiyao products in this field [2] - Significant growth in aerosol and plaster products, with a comprehensive marketing strategy integrating various channels and scenarios [2][3] - Online sales increased by over 20%, with a total of 48.45 million visitors and 3.54 million consumers generated through e-commerce platforms, resulting in a GMV of 254 million yuan [3] Group 2: Dividend Distribution - For the 2024 fiscal year, the company will distribute a cash dividend of 11.85 yuan per 10 shares, totaling approximately 2.16 billion yuan, which is 90.09% of the net profit attributable to shareholders [4] - The total cash dividend for 2024, including special dividends, amounts to 23.98 yuan per 10 shares, with a total of 4.28 billion yuan [4][5] - In the first half of 2025, a cash dividend of 10.19 yuan per 10 shares will be distributed, totaling 1.82 billion yuan, representing 50.05% of the net profit for that period [5] Group 3: Future Product Development - The Health Products Business Group aims to be a leader in high-quality health products, focusing on oral care and expanding the product ecosystem [6] - Continuous enhancement of the oral product line and development of new products to strengthen market position [6] Group 4: R&D Planning - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative pharmaceuticals [7] - Ongoing projects include 16 major traditional Chinese medicine varieties and 37 development projects, with a focus on innovative drug development [8] - Short-term projects aim to enhance existing products, while long-term projects focus on innovative drug development aligned with social needs and technological advancements [8]

Group 1: Meeting Overview - The investor meeting was held on January 23, 2026, at the company's headquarters [1] - Participants included representatives from Guotai Junan and Zhonghui Life Insurance [1] - The meeting was categorized as a telephone conference [1] Group 2: Company Representatives - The meeting was hosted by the Board Secretary, Qian Yinghui [1] - Investor relations management included Zhang Yu and Yang Kexin [1] Group 3: Main Discussion Points - The primary focus was to understand the company's production and operational status [1]